Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,473
Recruiting: 1,285
Ph III recruiting: 130
Growth YoY: +6.4%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,641)

clinicaltrialsPublishedShowing 151–200 of 3,460 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07586618	First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.(ALT-101)	recruiting	Phase 1	24	Allterum Therapeutics, IncINDUSTRY	1	Sep 1, 2026	clinicaltrials
NCT07479979	Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma	recruiting	Phase 1 / Phase 2	62	Natalie CallanderOTHER